Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal
Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will receive $500 million in upfront payments as well as a further $700 million if all development,